Use of anakinra in severe COVID 19: A case report
Abstract Coronavirus Disease 19 is a global healthcare emergency with high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID 19 successfully treated with IL 1 receptor antagonist (anakinra)
International Journal of Infectious Diseases